ReviewFrontiers in immunology2014
Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- The Role of Type I Interferons in Tuberculosis and in Tuberculosis-Risk-Associated Comorbidities.Infectious disease reports · 2025Review
- Type I interferons in bacterial diseases: myeloid cells at the crossroads of protection and pathology.Frontiers in immunology · 2025Review
- Interferon-β regulates proresolving lipids to promote the resolution of acute airway inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Cutting Edge: NOX2 NADPH Oxidase Controls Infection by an Intracellular Bacterial Pathogen through Limiting the Type 1 IFN Response.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Mycobacterium abscessus infection leads to enhanced production of type 1 interferon and NLRP3 inflammasome activation in murine macrophages via mitochondrial oxidative stress.PLoS pathogens · 2020Article
- Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?Frontiers in public health · 2020Article
- Myeloid Cell CK2 Regulates Inflammation and Resistance to Bacterial Infection.Frontiers in immunology · 2020Article
- Ligand-induced IFNGR1 down-regulation calibrates myeloid cell IFNγ responsiveness.Life science alliance · 2019Article
- IFN-β is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation.Nature communications · 2019Article
- Study of the immunogenicity ofIranian journal of basic medical sciences · 2019Article
- Tri-mannose grafting of chitosan nanocarriers remodels the macrophage response to bacterial infection.Journal of nanobiotechnology · 2019Article
- Peritoneal macrophages have an impaired immune response in obesity which can be reversed by subsequent weight loss.BMJ open diabetes research & care · 2019Article
- Crosstalk between type I and II interferons in regulation of myeloid cell responses during bacterial infection.Current opinion in immunology · 2018Review
- Effects of type I interferons in malaria.Immunology · 2018Review
- Host-Intrinsic Interferon Status in Infection and Immunity.Trends in molecular medicine · 2018Review
- Coactivation of TLR2 and TLR8 in Primary Human Monocytes Triggers a Distinct Inflammatory Signaling Response.Frontiers in physiology · 2018Article
- Down regulation of macrophage IFNGR1 exacerbates systemic L. monocytogenes infection.PLoS pathogens · 2017Article
- MHC Class II Activation and Interferon-γ Mediate the Inhibition of Neutrophils and Eosinophils by Staphylococcal Enterotoxin Type A (SEA).Frontiers in cellular and infection microbiology · 2017Article
- Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases.Frontiers in immunology · 2017Review
- Borrelia burgdorferi induces a type I interferon response during early stages of disseminated infection in mice.BMC microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type I interferons (IFNs) were first described for their ability to protect the host from viral infections and may also have beneficial effects under specific conditions within some bacterial infections. Yet, these pleiotropic cytokines are now known to exacerbate infections by numerous life-threatening bacteria, including the intracellular pathogens Listeria monocytogenes and Mycobacterium tuberculosis. The evidence that such detrimental effects occur during bacterial infections in both animals and humans argues for selective pressure. In this review, we summarize the evidence demonstrating a pro-bacterial role for type I IFNs and discuss possible mechanisms that have been proposed to explain such effects. The theme emerges that type I IFNs act to suppress myeloid cell immune responses. The evolutionary conservation of such anti-inflammatory effects, particularly in the context of infections, suggests they may be important for limiting chronic inflammation. Given the effectiveness of type I IFNs in treatment of certain autoimmune diseases, their production may also act to raise the threshold for activation of immune responses to self-antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.